CDM 050

Drug Profile

CDM 050

Alternative Names: CDM050

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kao Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Skin disorders

Most Recent Events

  • 04 Apr 2017 Kao Corporation completes a phase I trial in Healthy volunteers in Japan (UMIN000025668)
  • 26 Jan 2017 Phase-I clinical trials in Skin disorders in Japan (Topical) (UMIN000025668)
  • 16 Jan 2017 Kao Corporation plans a clinical trial for skin disorders in North America (UMIN000025668)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top